Today, Leavitt Partners, an HMA Company released a report outlining steps federal and state policymakers, technology and electronic health record (EHR) companies, health plans, pharmacies, and other healthcare providers can take to strengthen pharmacy data interoperability. As patients access more services from pharmacies, the data interoperability of those pharmacies becomes increasingly important to patients and … Read more

A RevCycleIntelligence article entitled “CMS Targets Value-Based Purchasing, Drug Costs to Reduce Spending” references the Leavitt Partners “Accountable Care Organizations and Risk-Based Payment Arrangements: Strong Preference for Upside-Only Contracts” white paper. The article states, “About 61 percent of ACO contracts contain only upside financial risk, meaning organizations do not have to repay financial losses, a … Read more

Digital health has experienced a rapid transformation in the last two years since the beginning of the COVID-19 pandemic, dramatically shifting how care is delivered to patients. To better understand the rapid changes occurring in the industry and capitalize on future market movements, Leavitt Partners has created a digital health taxonomy and standardized definitions, along with robust market segmentations and … Read more

Leavitt Partners examined publicly available resources to determine the 340B Drug Pricing Program’s (340B) impact on drug prices charged by both covered entities and pharmaceutical manufacturers. To answer these questions, Leavitt Partners undertook a comprehensive literature review of publicly available governmental reports, peer-reviewed journal articles, white papers, news articles, and other publicly available sources to … Read more

Nonadherence to a prescribed medication regimen for patients with chronic pain is associated with overall lower health outcomes, including increased hospital admissions, costs, and morbidity (quantitative review here). Deviations in timing, dosage, frequency, or duration of medication—all components of noncompliance—can cause medical reactions, increased pain, and medication use disorders, and can ultimately lead to emergency care … Read more

As efforts continued at the beginning of 2022 to implement the No Surprises Act aimed at preventing surprise medical bills that patients are often unable to pay, the Kaiser Family Foundation published a report that estimates nearly one in 10 adults have medical debt, and that Americans’ total medical debt could be as high as $195 billion. … Read more

Salt Lake City, March 16, 2021—Today, Leavitt Partners released “Using Modeling to Project Herd Immunity: When and how we will get back to normal,” a research paper outlining results from their current model to determine the expected timeline to reaching herd immunity from COVID-19. The research was conducted in response to growing interest in understanding … Read more

Cell and gene therapies (CGTs) are some of the most promising and exciting medical advancements taking place today. Some existing CGTs treat previously untreatable rare diseases, and there are hundreds of CGTs in clinical development to treat various types of cancer, hemophilia, sickle cell and other blood disorders, Alzheimer’s disease, and numerous rare conditions. The … Read more

Salt Lake City, June 25, 2020—Today, Leavitt Partners released “COVID-19 Hotspots,” a white paper that informs policymakers, industry leaders, and other key stakeholders to quickly assess where to deploy resources during the ongoing pandemic, and the accompanying, free tool that provides a daily updated map of where COVID-19 hotspots are forming in the United States. … Read more